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Abstract 
Continued growth of spending on drugs in Health care, especially in 
the public sector encouraged initiatives for reforms in the system of 
determining the prices of medicines. These initiatives that were undertaken, 
were primarily aimed at reducing the cost of drugs but parallel to become a 
generic medications simultaneously promoting an adjustment of 
reimbursement procedures in the pharmaceutical sector. The policies for the 
regulation of the pharmaceutical market come as a response to health care 
classical market failures. This article will focus on the features, 
implementation and impact of these policies in some EU member states. 
Most EU countries, apply the external reference system of prices, whereupon 
the price of a certain medication is determined based on the price of the same 
product in other countries. On the other hand, in twenty other EU member 
states, prices are determined by comparing the prices of the same products 
according to chemical, pharmacological or therapeutic grouping. The 
reference pricing system has been adopted by governments as a mechanism 
to reduce the costs in the public health care system. By setting a price limit, 
competition among producers has been stimulated. 
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Introduction 
 Legal regulations that deal with the determination of medication 
prices and their reimbursement comprise the greatest deal of organizing the 
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pharmaceutical system. The need for establishing a legal framework related 
to the determination of medication prices emerged as a result of the constant 
increase in the expenditure of medical products in healthcare, especially in 
the public sector. 
 All European countries are facing growing pharmaceutical 
expenditure, particularly in the public sector (OECD,2008) given that Europe 
has a comparatively higher coverage of publicly funded health care 
compared to the rest of the world (WHO, 2004). Based on this fact, in many 
EU countries there have been plenty of reforms in order to control the 
expenditures of medical products as well as promote generic medications 
with low prices as a mechanism to reduce the costs. In some European 
countries this system of regulation of medication prices dates back to late 
eighties and early nineties. Many European countries have alredy installed a 
reference pricing system as a reimbursement policy (Dylst et al.,2012). Pro-
generic drug policies applied in the form of reference pricing system, 
initially implemented in developed countries also includes the low and 
middle income countries (Kaplan et al.,2012). In this context, the national 
authorities are free to set the prices of medicinal products and to designate 
the treatments that they wish to reimburse under their social security system. 
However, the European Union has defined a common procedural framework 
through the adoption of Council Directive 89/105/EEC, which is generally 
known as the "Transparency Directive". This instrument aims to ensure that 
national pricing and reimbursement decisions are made in a transparent 
manner and do not disrupt the operation of the Internal Market (Council 
Directive 89/105/EEC,1988) 
 This paper aims at reviewing policies that determine medication 
prices and their reimbursement in EU member countries, focusing on the 
characteristics, application and consequences of these policies by promoting 
generic medications in some EU countries and we will also analyze the 
“Methodology on the manner of estabilishment of medication prices“ in 
Macedonia and the consequences that derive from this system. 
 
Methods 
 Research carried out based on  National Price Sources, international 
literature, scientific articles. Research in the literature has focused on items 
that aim at analyzing the consequences of reference pricing system in the EU 
countries and studies conducted in recent years, mainly from 2012 that 
highlighted generic medicine pricing in Europe. Search terms 
included,“medicines“, „pricing“, „generics“, „refernce pricing“, „EU 
countries“. 
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Results 
 In 2010, EU member states devoted on average (unweighted) 9.0% of 
their GDP to health expenditures, significantly higher than 7.3% in 2000, but 
slightly lower than the peak of 9.2% reached in 2009. Following the 
economic crisis, which started in many countries, public expenditures on 
health were maintained in 2009 while GDP was falling strongly, but this was 
followed in 2010 by the implementation of a range of measures to reduce 
government health spending as a part of broader efforts to reduce large 
budgetary deficits and debts (OECD,2012). Parallel to the increase of 
expenditures in healthcare, there has been a considerable increase in 
pharmaceutical expenditures, which has caused policy makers in the field of 
healthcare in EU countries focus on lowering their prices.  They are aware 
that by correctly regulating the pharmaceutical market, savings are possible 
without compromising the quality in healthcare. Policies that promote the 
usage of generic medications are often at the front of attempts to increase the 
cost-effectiveness of medical products. The implementation of the Reference 
Pricing System in many EU countries and those looking forward to their 
accession marks an important step in controlling the price of reimbursed 
medications. In Europe, this system was adopted in countries with high 
medication prices and then widely spread in many other European countries. 
This system enables involved parties to determine an acceptable price level 
for “equivalent” medications with huge difference in price (set by the 
producers). The reference price of a medical product implies the maximal 
amount, which is reimbursed by the Healthcare Insurance Fund. If the price 
of a medical product is higher than the reference price, then the patient pays 
only the difference between the price of a medical and the reference price or 
h/she gets a comparable therapeutic product (without additional charges). It 
is interesting to note that seven EU member states did not implement 
(Ireland, the United Kingdom, Austria, Luxembourg, Cyprus and Malta) or 
abandoned (Sweden) a reference price system in 2002(Vrijens et al.,2010); 
however, there are other systems that motivate the prescription of generic 
medications in these countries. 
 Based on a review of the Reference Pricing System (RPS) in some 
EU countries, three main differences have been noticed: 
o The way the system has been organized (which medications are 
included). 
o The way the reference price has been set, and 
o The measures (for physicians, pharmacists and patients) taken to 
stimulate the use of low cost drugs. 
 Different EU countries implement different systems in setting the 
prices. In most EU countries, the price of medications is determined based on 
the external reference pricing system. 
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External reference pricing 
 Applied in 24 EU Member States (except Denmark, Sweden and the 
UK), it is a form of price control by setting a maximum price, based on the 
price of the same product in another country (Kanavos et al.,2011). Countries 
choose mostly the lowest or an average price within the specified basket of 
prices of other countries. The choice of reference countries made based on 
the level of economic development and geographical proximity that enables 
the determination of an acceptable price.  
 
Internal reference pricing 
 20 EU Member States set the price to be paid by the public payers by 
comparing prices of equivalent or similar products in a chemical, 
pharmacological or therapeutic group. The reference price of a medical 
product implies the maximal amount, which is reimbursed by a third payer 
(“reference price”). The patient pays the difference between the retail price 
and the “reference price”. A condition for IRP is to have therapeutically 
interchangeable medicines, often generics, available on the market.  
 The way the value of the reference price is going to be set, different 
EU countries implement different methods of determining the prices. The 
reference price is generally calculated as a function of market prices of 
medicines. 
 
Different methods of calculating the referent price 
 In different European countries apply different methods to set 
reference prices. A country may employ one or a combination of methods to 
establish reference prices(Dylst et al.,2012). Some of methods to set refernce 
price are as follows: 
 Based on the lowest priced medications (applied in some countries 
such as: Denmark, Italy, Poland, Slovenia, France, Hungary, Turkey) 
 Based on the percentage of original drug (Belgium)  
 Based on the econometric model (Germany) 
 Based on the average price of medications (Croatia, Hungary) 
 
The measures (for physicians, pharmacists and patients) 
 It is important that during the drafting of policies on setting 
medication prices, the implementation of policy measures should be carried 
out having in mind the characteristics of that particular country. Even though 
the experience from other countries is used as e point of reference, it is not 
always easy to adapt these policies in countries with different socio-
economic peculiarities (Carone et al.,2012) 
 Measures focused on the physicians - in all countries, physicians are 
obliged to prescribe generic medications (INN) and respect the guidelines for 
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treating illnesses. In some countries (France, Germany, Spain) they have 
direct financial incentives to prescribe low cost drugs (Vrijens et al.,2010). 
 Measures focused on the pharmacists -in all countries, pharmacists 
are mandated to distribute cheaper bio-equivalent medications. In some 
countries (France, Germany, Spain) they have direct financial incentives to 
dispense  low cost drugs. It is worth mentioning that in developing countries 
there is still collaboration between pharmaceutical companies and 
pharmacists, who are rewarded for distributing the company-specific 
medications. 
 Measures focused on the patients – awareness and information about 
rational utilization of medications such as antibiotics in some of the 
developing countries.  
 
Pharmaceutical pricing in the Republic of Macedonia 
 Within the numerous reforms undertaken in recent years in the 
pharmaceutical sector in the Republic of Macedonia, can be said that a great 
achievement was realized with the implementation of „ Methodology on the 
manner of estabilishment of medication prices“ in 2011. This Methodology 
defines the manner of establishing the wholesale and retail prices of drugs 
that have obtained Marketing Authorization, issued by the Agency for Drugs 
(hereinafter “the Agency”) and are prescription medications. The reference 
countries, within the meaning of this methodology, are as follows: Republic 
of Slovenia, Republic of Bulgaria, the Netherlands, Republic of Poland, the 
United Kingdom, Republic of France, Republic of Croatia, Republic of 
Serbia, Republic of Greece, Federal Republic of Germany, Republic of 
Turkey and the Russian Federation. (Official Gazette RoM). Limitation of 
price for producers on the one hand and the promotion of generic drugs 
through mechanisms other than brought a continuous increase in the number 
of reimbursable drugs on the positive list, especially the part that drugs with 
a minimum additional payment. The Health Insurance Fund reported that in 
2013 the total of 391 generic drugs that are included in the positive list, 299 
are provided at no additional charge or 76.5%, which constitutes a major 
difference compared to 2009 when the figure was only 20% of the drugs 
included in the positive list. In this context, the increasing number of drugs 
without additional payment reached a mutual savings of financial 
instruments for the insured as well as  for Health Insurance Fund( Tulevska 
E et al.,2014) 
 
Conclusion 
 Pharmaceutical policies have been adopted as a mechanism by 
governments to reduce the cost of expenses in the public healthcare system.  
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 By setting a limit price, competition among producers is fostered. 
The establishment of a reference value also makes the patients more aware of 
the medication prices. The determination of prices by using this system 
influences the compilation of positive lists whose main objective should be 
cost-saving. Policies are targeted toward pharmacists and physicians. For 
pharmacists, generic substitution offers the obligation to dispense the 
cheapest equivalent medicine. Physicians may face a number of regulations: 
monitoring of their prescription patterns, prescription guidelines, budget 
ceilings and educational and informational policies. 
 However, even though this system has been implemented in almost 
all European countries, there are still no sufficient analyses of the achieved 
results and outcomes.  
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